secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001104659-25-073909
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q2 revenue falls 18% to $13.5M; net loss $67.8M; SOL-1 data Q1 2026
--------------------------------------------------------------------------------

- Q2 net revenue $13.5M, down 18% YoY; DEXTENZA unit sales up 5% but net revenue pressured by reimbursement challenges.
- Net loss $67.8M ($0.39/share) vs $43.8M ($0.26) YoY; R&D spend $51.1M (up 77%) driven by SOL trial costs.
- Cash $391.1M; raised ~$97M via ATM in June; runway into 2028, well beyond SOL-1 and SOL-R data.
- SOL-1 Phase 3 wet AMD top-line data on track for Q1 2026; SOL-R data expected 1H 2027 with streamlined rescue criteria.
- Received FDA feedback on NPDR/DME program; Investor Day Sept 30 in NYC to detail strategy and commercial outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/0001104659-25-073909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-073909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer